8
Jan
2016

All the Biotech Deals and Financings You Can Grok Before JP Morgan 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Vigil, Inozyme Acquired, Prime Cuts, & Regeneron Scoops Up 23andMe
Genentech’s Bet on NC, GSK Buys Boston Liver Drug, & Septerna Entices Novo
NewLimit’s Anti-Aging Bounty, a Twist Spinout, & AI Coming to the FDA
FDA in Crisis, Parker Institute Snags Big Fish, & Merida Megaround